AbbVie Inc. (ABBV)

80.85
NYSE : Health Technology
Prev Close 80.52
Day Low/High 80.16 / 81.70
52 Wk Low/High 75.77 / 122.00
Avg Volume 6.58M
Exchange NYSE
Shares Outstanding 1.50B
Market Cap 121.12B
P/E Ratio 16.71
Div & Yield 4.28 (4.89%)

Latest News

Dividend Aristocrats Welcome a New Class of Nobility

Of the 57 index constituents, four Aristocrats have yields above 4.0%.

Watch Out for the Wave: Cramer's 'Mad Money' Recap (Tuesday 1/29/19)

Watch Out for the Wave: Cramer's 'Mad Money' Recap (Tuesday 1/29/19)

Jim Cramer says that if expectations are too high, even a great quarter cannot save you from the wave of selling.

Carvana, Bank OZK, Idexx Labs: 'Mad Money' Lightning Round

Carvana, Bank OZK, Idexx Labs: 'Mad Money' Lightning Round

Jim Cramer takes a look at Carvana, Bank OZK, Idexx Labs, Patterson-UTI Energy, 3D Systems, AbbVie and more.

Dow Closes Higher to End Week With Modest Gains

Dow Closes Higher to End Week With Modest Gains

Stocks rose by Friday's close, getting a boost from a number of strong corporate earnings reports even as investors continue to worry about a lack of progress in U.S.-China trade talks.

AbbVie Falls After Missing Top- and Bottom-Line Estimates

AbbVie Falls After Missing Top- and Bottom-Line Estimates

The pharmaceutical company reports fourth-quarter results below analysts' consensus forecasts.

Why Risk-On Is In Vogue, Updating Zuora: Market Recon

Why Risk-On Is In Vogue, Updating Zuora: Market Recon

China's central bank announced a bill swap mechanism late Thursday aimed at slowing down the nation's economic slowdown.

AbbVie Reports Full-Year And Fourth-Quarter 2018 Financial Results

AbbVie Reports Full-Year And Fourth-Quarter 2018 Financial Results

- Reports Full-Year Diluted EPS of $3.66 on a GAAP Basis; Adjusted Diluted EPS of $7.91 Reflects Growth of 41.3 Percent

AbbVie Provides Update On Phase 3 Study Of Ibrutinib (IMBRUVICA®) In Metastatic Pancreatic Cancer

AbbVie Provides Update On Phase 3 Study Of Ibrutinib (IMBRUVICA®) In Metastatic Pancreatic Cancer

-- The RESOLVE (PCYC-1137) trial evaluated ibrutinib in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Flexible, Patient Fed: Cramer's 'Mad Money' Recap

Flexible, Patient Fed: Cramer's 'Mad Money' Recap

Jim Cramer talks about the Fed, and outlines your game plan.

Qualcomm, Momo, Ciena: 'Mad Money' Lightning Round

Qualcomm, Momo, Ciena: 'Mad Money' Lightning Round

Jim Cramer weighs in on Qualcomm, Momo, Ciena, AbbVie, LM Ericsson and more.

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Jim Cramer says a trade deal could help, but what matters after today is earnings -- and how bad the shortfalls will be.

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

AbbVie And Tizona Therapeutics Announce Strategic Collaboration To Develop First-in-Class Immunotherapy For Cancer Targeting CD39

AbbVie And Tizona Therapeutics Announce Strategic Collaboration To Develop First-in-Class Immunotherapy For Cancer Targeting CD39

- Initiation of clinical studies with TTX-030 is targeted in Q1 2019

AbbVie To Host Fourth-Quarter And Full-Year 2018 Earnings Conference Call

AbbVie To Host Fourth-Quarter And Full-Year 2018 Earnings Conference Call

NORTH CHICAGO, Ill., Jan.

3 Key Bear Market Rules, 5 Bargain Buys and a Monthly Dividend Portfolio

3 Key Bear Market Rules, 5 Bargain Buys and a Monthly Dividend Portfolio

Dow Theory presents tips for surviving a bear market, some top year-end stock bargains and a simple strategy for monthly income.

AbbVie: The Perfect Stock for High Yield and Growth

ABBV offers an ideal mix of growth, value and income.

AbbVie Submits New Drug Application To U.S. FDA And Marketing Authorization Application To EMA For Upadacitinib For Treatment Of Adults With Moderate To Severe Rheumatoid Arthritis

AbbVie Submits New Drug Application To U.S. FDA And Marketing Authorization Application To EMA For Upadacitinib For Treatment Of Adults With Moderate To Severe Rheumatoid Arthritis

- Regulatory applications supported by robust SELECT Phase 3 program evaluating more than 4,000 patients with moderate to severe rheumatoid arthritis[1-5]

AbbVie To Present At The 37th Annual J.P. Morgan Healthcare Conference

AbbVie To Present At The 37th Annual J.P. Morgan Healthcare Conference

NORTH CHICAGO, Ill., Dec.

AbbVie Announces Executive Leadership Changes

AbbVie Announces Executive Leadership Changes

NORTH CHICAGO, Ill., Dec.

AbbVie Announces $5 Billion Increase To Stock Repurchase Program

AbbVie Announces $5 Billion Increase To Stock Repurchase Program

NORTH CHICAGO, Ill., Dec.

How to Invest in Cannabis - In Its Many Forms

How to Invest in Cannabis - In Its Many Forms

As cannabis becomes more and more legal, investors have started to wonder what that means for them.

Phase 3 Trial Of Rova-T As Second-line Therapy For Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted

Phase 3 Trial Of Rova-T As Second-line Therapy For Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted

- Independent Data Monitoring Committee responsible for ongoing review of study data recommended enrollment be stopped

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus The Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide And Rituximab) In Previously Untreated And Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data At ASH 2018

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus The Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide And Rituximab) In Previously Untreated And Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data At ASH 2018

- Results from this interim analysis showed ibrutinib plus rituximab prolonged progression-free survival (PFS) compared to a standard chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab (FCR) at nearly 3 years of follow-up (abstract #LBA-4)

IMBRUVICA® (ibrutinib) Phase 3 Combination Data With Obinutuzumab Finds Significant Improvement In Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy Of Chlorambucil Plus Obinutuzumab For Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

IMBRUVICA® (ibrutinib) Phase 3 Combination Data With Obinutuzumab Finds Significant Improvement In Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy Of Chlorambucil Plus Obinutuzumab For Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

- These data were included in the recent sNDA accepted by the U.S. FDA, which received Priority Review, and could lead to the first chemotherapy-free anti-CD20 combination approved for first-line CLL treatment

IMBRUVICA® (ibrutinib) Data In Chronic Lymphocytic Leukemia (CLL) Show Up To Seven Years Of Progression-free Survival (PFS) In 80 Percent Of Previously Untreated Patients, The Longest Follow-up For A Bruton's Tyrosine Kinase Inhibitor To Date

IMBRUVICA® (ibrutinib) Data In Chronic Lymphocytic Leukemia (CLL) Show Up To Seven Years Of Progression-free Survival (PFS) In 80 Percent Of Previously Untreated Patients, The Longest Follow-up For A Bruton's Tyrosine Kinase Inhibitor To Date

- With up to seven years of treatment, sustained PFS rates with ibrutinib in CLL/small lymphocytic lymphoma (SLL) at 80 percent for previously untreated patients

AbbVie Presents New Data From Phase 3 MURANO Trial Of VENCLEXTA®/VENCLYXTO® (venetoclax) In Combination With Rituximab In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed The Fixed Treatment Course

AbbVie Presents New Data From Phase 3 MURANO Trial Of VENCLEXTA®/VENCLYXTO® (venetoclax) In Combination With Rituximab In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed The Fixed Treatment Course

- The data demonstrated that VENCLEXTA®/VENCLYXTO® in combination with rituximab (VenR) reduced the risk of disease progression or death compared to a standard of care, bendamustine plus rituximab (BR), after a median three-year follow-up[1]

TheStreet Quant Rating: B- (Buy)